tbuckley/cabot-search huggingface dataset:
Effectiveness of insecticide-treated bednets in malaria prevention in Haiti: a case-control study
Authors: Laura C Steinhardt, Yvan St Jean, Daniel Impoinvil, Kimberly E Mace, Ryan Wiegand, Curtis S Huber, Jean Semé Fils Alexandre, Joseph Frederick, Emery Nkurunziza, Samuel Jean, Brian Wheeler, Ellen Dotson, Laurence Slutsker, S Patrick Kachur, John W Barnwell, Jean Frantz Lemoine, Michelle A Chang
Journal: The Lancet Global Health (2016)

Insecticide-treated bednets (ITNs) are effective in preventing malaria where vectors primarily bite indoors and late at night, but their effectiveness is uncertain where vectors bite outdoors and earlier in the evening. We studied the effectiveness of ITNs following a mass distribution in Haiti from May to September, 2012, where the Anopheles albimanus vector bites primarily outdoors and often when people are awake.In this case-control study, we enrolled febrile patients presenting to outpatient departments at 17 health facilities throughout Haiti from Sept 4, 2012, to Feb 27, 2014, who were tested with malaria rapid diagnostic tests (RDTs), and administered questionnaires on ITN use and other risk factors. Cases were defined by positive RDT and controls were febrile patients from the same clinic with a negative RDT. Our primary analysis retrospectively matched cases and controls by age, sex, location, and date, and used conditional logistic regression on the matched sample. A sensitivity analysis used propensity scores to match patients on ITN use propensity and analyse malaria among ITN users and non-users. Additional ITN bioefficacy and entomological data were collected.We enrolled 9317 patients, including 378 (4%) RDT-positive cases. 1202 (13%) patients reported ITN use. Post-hoc matching of cases and controls yielded 362 cases and 1201 matched controls, 19% (333) of whom reported consistent campaign net use. After using propensity scores to match on consistent campaign ITN use, 2298 patients, including 138 (7%) RDT-positive cases, were included: 1149 consistent campaign ITN users and 1149 non-consistent campaign ITN users. Both analyses revealed that ITNs did not significantly protect against clinical malaria (odds ratio [OR]=0·95, 95% CI 0·68-1·32, p=0·745 for case-control analysis; OR=0·95, 95% CI 0·45-1·97, p=0·884 for propensity score analysis). ITN and entomological data indicated good ITN physical integrity and bioefficacy, and no permethrin resistance among local mosquitoes.We found no evidence that mass ITN campaigns reduce clinical malaria in this observational study in Haiti; alternative malaria control strategies should be prioritised.The Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the US-based Centers for Disease Control and Prevention (CDC).
Detection of CD55- and CD59-Negative Immature Reticulocytes May Improves Sensitivity/Specificity to Identify a Minor Population of PNH-Type Cells in Patients with Myelodysplastic Syndrome/Aplastic Anemia
Authors: Naoshi Obara, Shoko Satoh, Yasushi Okoshi, Shigeru Chiba, Haruhiko Ninomiya
Journal: Blood (2011)
Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia
Authors: Naveen Pemmaraju, Hagop M. Kantarjian, Susan O'Brien, Tapan M. Kadia, Jorge E. Cortes, Gautam Borthakur, Stefan Faderl, Guillermo Garcia-Manero, Zeev Estrov, Farhad Ravandi, Alfonso Quintas-Cardama, Elias J. Jabbour, Charles Asa Koller, Sara E Dellasala, Sherry A. Pierce, Elizabeth M Burton, Srdan Verstovsek
Journal: Blood (2012)
AB0056 Downregulation of Tumor Necrosis Factor and Interleukin-1 by Ellagic Acid
Authors: S.-H. Park, H. Lee, J.-Y. Choe, S.-K. Kim, C.W. Lee, J.-W. Kim, J. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ellagic acid (EA) is a phenolic constituent in fruits and nuts, such as raspberries, strawberries, walnuts, mango kernel and pomegranate. It was documented that EA shows anti-fibrotic, anti-inflammatory activity in vivo model of bowel inflammation and lung fibrosis, however the precise mechanism of signal inhibition was not extensively investigated. <h3>Objectives</h3> The objectives of this study are first, to elucidate the anti-inflammatory effect of EA in RAW 264.7 murine macrophage cell line by NF-kB pathway in vitro, and second, to compare it with effect of other immuno-modulating agent, tacrolimus and colchicine. <h3>Methods</h3> We determined the cytotoxic effect of EA using MTT assay. The effects of EA on tumor necrosis facor (TNF)-alpha induced mRNA and protein expression were investigated using quantitative real-time PCR and western blot. In addition, we examined the effects of pharmaceutical drugs with anti-inflammatory properties on expression of TNF-alpha. <h3>Results</h3> EA significantly suppressed the expression of interleukin-1 beta and TNF-alpha in a dose dependent manner. EA suppressed TNF-alpha induced inflammatory genes expression by inhibiting the phosphorylation of JNK and Akt, whereas had no significant effect on p38 activation. In addition, the inhibitory effect of EA on TNF-alpha induced inflammatory genes expression was regulated by suppression of IkB-alpha phosphorylation and NF-kB translocation. The expression of TNF-alpha mRNA level was reduced comparably treated with EA and other anti-inflammatory agents (ascorbic acid, dexamethasone and colchicine). <h3>Conclusions</h3> These findings suggest that EA suppresses inflammatory genes expression through phosphorylation of JNK/Akt and regulation of NF-kB signal pathway in TNF-alpha induced inflammation. Further investigation regarding effects of EA on autoimmune, inflammatory is scheduled. <h3>References</h3> S. Corbett, J. Daniel, R. Drayton, M. Field, R. Steinhardt, N. Garrett, Evaluation of the anti-inflammatory effects of ellagic acid, J. Perianesth. Nurs. 25 (2010), 214–220. S. Ahmed, A. Rahman, M. Saleem, M. Athar, S. Sultana, Ellagic acid ameliorates nickel induced biochemical alterations: diminution of oxidative stress, Hum. Exp. Toxicol. 18 (1999) 691–698. <h3>Disclosure of Interest</h3> None declared
OP0059 Serum CXCL10 Levels Are Associated with Clinical Manifestations and Disease Activity in Behcet's Disease
Authors: S.J. Lee, E.H. Kang, B.Y. Choi, S.E. Kang, S.H. Shon, J.S. Park, J.K. Park, E.Y. Lee, E.B. Lee, Y.W. Song
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Chemokines are multifunctional mediators that control leukocyte recruitment into the inflammatory sites and enhance immune responses. It remains to be investigated which chemokines are important in Behcet9s disease (BD). <h3>Objectives</h3> The objective of this study was to investigate serum levels of (C-X-C motif) CXC chemokines in BD patients and its association with clinical manifestations and disease activity. <h3>Methods</h3> Blood samples were collected from 109 BD patients and 34 age-, sex matched healthy controls (HCs). Twenty two follow-up samples were collected in BD patients. Serum CXC chemokines were assayed for the neutrophil chemoattractants (CXCL1 and CXCL8) and lymphocyte chemoattractants (CXCL9, CXCL10, CXCL12, CXCL13 and CXCL16) by using a multiplex assay. Cell surface makers such as CD3, CD4 and CXCR3 in peripheral blood mononuclear cells were investigated by flow cytometry. The clinical features including disease activity, laboratory tests and current medication were evaluated at the time of blood collection. C-X-C chemokine receptor 3 (CXCR3) expression in skin and intestinal lesions from BD patients were assessed via immunohistochemistry. <h3>Results</h3> Serum levels of CXCL8, CXCL10 and CXCL12 were significantly higher in the BD patients than in HC (p=0.001, p=0.007 and p=0.003, respectively). Serum CXCL10 levels were significantly correlated with disease activity in both Behcet9s Disease Current Activity Form (BDCAF) and Behcet9s Syndrome Activity Score (BSAS) (rho =0.336, p&lt;0.001 and rho =0.253, p=0.009, respectively) as well as with number of genital ulcer and erythema nodosum (EN) (rho =0.222, p=0.020 and rho =0.329, p&lt;0.001, respectively). In follow-up BD patients, changes of serum CXCL10 levels were correlated with those of BDCAF (rho =0.425, p=0.048). CXCR3 receptor expression was significantly increased on CD3 positive T cells versus CD3 negative cells in peripheral blood mononuclear cells of both BD patients and HCs (p=0.009 and p=0.031, respectively). Levels of serum CXCL10 were inversely correlated with percentage of CXCR3 expression on CD3 positive T cells in BD patients (rho = -0.523, p=0.022). In immunohistochemistry, the CXCR3 positive inflammatory cells were increased in skin lesions of BD patients than in those of HCs. <h3>Conclusions</h3> These results suggest that CXCL10/CXCR3 axis contribute to pathogenesis of BD particularly mucocutaneous lesions. Measurement of serum CXCL10 may help to assess disease activity in BD patients. <h3>Disclosure of Interest</h3> None declared
Combinatorial Epigenetic Aberration Propagates in Myelodysplastic Syndrome in the Setting of Concurrent Loss of Tet2 and Ezh2
Authors: Nagisa Hasegawa, Goro Sashida, Motohiko Oshima, Hirotaka Matsui, Atsunori Saraya, Changshan Wang, Tomoya Muto, Chiaki Nakaseko, Koutaro Yokote, Atsushi Iwama
Journal: Blood (2015)
ATNT-11A PHASE I PHARMACODYNAMIC STUDY OF DISULFIRAM AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA AFTER RADIATION THERAPY AND CONCURRENT TEMOZOLOMIDE
Authors: Jiayi Huang, Jian Campian, Amit Gujar, David Tran, A. Craig Lockhart, Todd DeWees, Christina Tsien, Albert Kim
Journal: Neuro-Oncology (2015)

BACKGROUND: Preclinical studies have shown that disulfiram (DSF) has promising activity against glioblastoma (GBM) and is synergistic with temozolomide (TMZ). These studies have also suggested that the mechanism is related to the inhibition of proteasomal activity. METHODS: We conducted an open-label, dose-escalation pharmacodynamic study to combine DSF with maintenance TMZ for newly diagnosed GBM after radiation therapy (RT) and concurrent TMZ. The pharmacodynamic effect of DSF on proteasome inhibition was evaluated on peripheral bloods cells, with complete inhibition defined as at least 5 patients with 95% proteasome inhibition in a given cohort. Dose escalation occurred if both incomplete proteasome inhibition and less than 2 dose-limiting toxicities (2 DLTs) were observed in cohort 1. Cohort 1 and 2 received DSF 500 mg and 1000 mg daily, respectively. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which at least 2 patients of a cohort experienced DLT during the first month of disulfiram. The primary endpoint was to assess the magnitude of proteasome inhibition by DSF. The secondary endpoint was to determine the MTD of DSF with TMZ. RESULTS: Seven patients were enrolled in cohort 1 (median duration of DSF: 55 days, range: 24-165), and five patients in cohort 2 (median: 15 days, range: 15-33). No DLT was observed in cohort 1, but 4 of 5 patients in cohort 2 stopped DSF during the first month due to toxicity, including 3 DLTs. Incomplete proteasome inhibition was observed at 500 mg level. Six of 7 patients in cohort 1 had progressed, with a median time to progression of 3.6 months (range: 1.6-6.8) from the start of DSF or 6.2 months (range: 4.2-9.5) from the start of RT. CONCLUSIONS: The MTD of DSF with TMZ is 500 mg daily, which is associated with incomplete proteasome inhibition.
Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition
Authors: Neerav Shukla, Maureen M. O'Brien, Lewis B. Silverman, Melinda Pauly, Cynthia Wetmore, Mignon L. Loh, James A. Whitlock, Patrick Brown, Blythe Thomson, Stephen J. Blakemore, Scott Daigle, Patricia Pimentel, Nigel J. Waters, Andrei V Krivstov, Richard Koche, Scott A. Armstrong, Peter T Ho, Lia Gore
Journal: Blood (2015)
Neuropeptides Orexin A and B Are Funktionally Aktive in CD34+ Hematopoietic Stem and Progenitor Cells.
Authors: Ron-Patrick Cadeddu, Akos G. Czibere, Sebastian Büst, Johannes C Fischer, Ulrich Steidl, Ralf Kronenwett, Guido Kobbe, Rainer Haas, Ingmar Bruns
Journal: Blood (2009)
Bortezomib Resistant Multiple Myeloma Cells Are Tumor Initiating Cells That Have a Stem Cell-Like Genetic Signature.
Authors: Juwon Park, Chansu Lee, Jeong-In Oh, Byung-Su Kim, Jung Hye Kwon, Byoung Kook Kim, Kwang-Sung Ahn, Sung-Soo Yoon
Journal: Blood (2009)
A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.
Authors: Antonio Palumbo, Alessandra Larocca, Cecilia Rus, Francesca Gay, Davide Rossi, Patrizia Pregno, Patrizia Falco, Ilaria Avonto, Valeria Magarotto, Federica Cavallo, Massimo Iacobelli, Gianluca Gaidano, Constantine Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Mario Boccadoro
Journal: Blood (2007)
Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin’s Lymphoma.
Authors: John P. Perentesis, Doojduen Villaluna, Stella M. Davies, Xiaowen Zhai, Gretchen A. Radloff, Michael A. Weiner, Richard Sposto, Kara M. Kelly
Journal: Blood (2006)
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not “high risk”: Diagnosis, management, and clinical outcomes in a series of 115 cases
Authors: Toru Ogawa, Maija Kiuru, Thomas H. Konia, Maxwell A. Fung
Journal: Journal of the American Academy of Dermatology (2016)
Prophylactic Low-Dose Aspirin Is Effective as Antithrombotic Therapy in Patients Receiving Combination Thalidomide or Lenalidomide.
Authors: Ruben Niesvizky, Deborah M. Martinez-Banos, Udi Y. Gelbshtein, Hearn J. Cho, Roger N. Pearse, Faiza Zafar, Karen Pekle, Richard Furman, John P. Leonard, Morton Coleman
Journal: Blood (2005)
A soft, wearable microfluidic device for the capture, storage, and colorimetric sensing of sweat
Authors: Ahyeon Koh, Daeshik Kang, Yeguang Xue, Seungmin Lee, Rafal M. Pielak, Jeonghyun Kim, Taehwan Hwang, Seunghwan Min, Anthony Banks, Philippe Bastien, Megan C. Manco, Liang Wang, Kaitlyn R. Ammann, Kyung-In Jang, Phillip Won, Seungyong Han, Roozbeh Ghaffari, Ungyu Paik, Marvin J. Slepian, Guive Balooch, Yonggang Huang, John A. Rogers
Journal: Science Translational Medicine (2016)

A soft, skin-mounted microfluidic device captures microliter volumes of sweat and quantitatively measures biochemical markers by colorimetric analysis.
Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
Authors: Asher Chanan-Khan, Jeffrey L Wolf, Juan Garcia, Mecide Gharibo, Sundar Jagannath, Debbie Manfredi, Taimur Sher, Cindi Martin, Sybil H Zildjian, James O'Leary, Robert Vescio
Journal: Blood (2010)
National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013
Authors: Joseph A. Salami, Haider Warraich, Javier Valero-Elizondo, Erica S. Spatz, Nihar R. Desai, Jamal S. Rana, Salim S. Virani, Ron Blankstein, Amit Khera, Michael J. Blaha, Roger S. Blumenthal, Donald Lloyd-Jones, Khurram Nasir
Journal: JAMA Cardiology (2016)

Statins remain a mainstay in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD).To detail the trends in use and total and out-of-pocket (OOP) expenditures associated with statins in a representative US adult population from 2002 to 2013.This retrospective longitudinal cohort study was conducted from January 2002 to December 2013. Demographic, medical condition, and prescribed medicine information of adults 40 years and older between 2002 and 2013 were obtained from the Medical Expenditure Panel Survey database.Estimated trends in statin use, total expenditure, and OOP share among the general adult population, those with established ASCVD, and those at risk for ASCVD. Costs were adjusted to 2013 US dollars using the Gross Domestic Product Index.From 2002 to 2013, more than 157 000 Medical Expenditure Panel Survey participants were eligible for the study (mean [SD] age, 57.7 [39.9] years; 52.1% female). Overall, statin use among US adults 40 years of age and older in the general population increased 79.8% from 21.8 million individuals (17.9%) in 2002-2003 (134 million prescriptions) to 39.2 million individuals (27.8%) in 2012-2013 (221 million prescriptions). Among those with established ASCVD, statin use was 49.8% and 58.1% in 2002-2003 and 2012-2013, respectively, and less than one-third were prescribed as a high-intensity dose. Across all subgroups, statin use was significantly lower in women (odds ratio, 0.81; 95% CI, 0.79-0.85), racial/ethnic minorities (odds ratio, 0.65; 95% CI, 0.61-0.70), and the uninsured (odds ratio, 0.33; 95% CI, 0.30-0.37). The proportion of generic statin use increased substantially, from 8.4% in 2002-2003 to 81.8% in 2012-2013. Gross domestic product-adjusted total cost for statins decreased from $17.2 billion (OOP cost, $7.6 billion) in 2002-2003 to $16.9 billion (OOP cost, $3.9 billion) in 2012-2013, and the mean annual OOP costs for patients decreased from $348 to $94. Brand-name statins were used by 18.2% of statin users, accounting for 55% of total costs in 2012-2013.Statin use increased substantially in the last decade among US adults, although the uptake was suboptimal in high-risk groups. While total and OOP expenditures associated with statins decreased, further substitution of brand-name to generic statins may yield more savings.
AB0557 Behçet's Disease in Women: A Tunisian Series of 135 Patients
Authors: T. Ben Salem, M. Tougorti, I. Naceur, I. Ben Ghorbel, M. Lamloum, M.H. Houman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The aim of this study was to describe clinical and genetic characteristics of Behçet9s disease (BD) in women and to compare them with those in men. <h3>Methods</h3> 430 cases of patients with BD (fulfilling criteria of the International Study Group for BD) were studied. Clinical and genetic characteristics of women with BD were noted, than compared to those observed in male BD patients. Data were compared using the Chi2 test and the Fisher exact test. <h3>Results</h3> 135 women were studied; the mean age at the onset of the BD was at 28.7 years. The average age at BD diagnosis was 34.64 years. Genital aphtosis was noted in 71.9% of patients and skin lesions in 83% (pseudofolliculitis: 63.7%, erythema nodosum: 28.9% and positive pathergy test: 56.6%). Ocular involvement in type of uveitis was noted in 43% of patients and retinal vasculitis in 23.7% of them. 65% of women complained of arthralgia while only 7.4% of them presented arthritis. Neurological manifestations were objectified in 31.9% of patients. Deep vein thrombosis (DVT) and arterial disease were noted respectively in 15.6% and 0.7% of cases. HLA B51 was present in 47.7% of women with BD in our series. Compared to male patients, women had significantly less genital aphtosis (71.9% vs 83%, p=0.008), pseudofolliculitis (63.7% vs 79.6%, p&lt;0.0001), DVT (15.6% vs 33.2%, p&lt;0.0001) and arterial disease (0.7% vs 9.2%, p=0.001). On the contrary, arthralgia (65% vs 47.5%, p=0.007) and erythema nodosum (28.9% vs 11.6%, p&lt;0.0001) were significantly more frequent in women. <h3>Conclusions</h3> Our results were similar to other BD series regarding the high incidence of erythema nodosum and joint manifestations in women, and the lower frequencies of genital aphtosis and vascular involvements compared to men. <h3>Disclosure of Interest</h3> None declared
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation
Authors: Mark J. Levis, Alexander E Perl, Hervé Dombret, Hartmut Döhner, Björn Steffen, Philippe Rousselot, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Guy Gammon, Denise Trone, Eugen Leo, Jorge E Cortes
Journal: Blood (2012)
Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.
Authors: Francisco Cervantes, Eduardo Arellano-Rodrigo, Alberto Alvarez-Larran, Juan-Carlos Reverter, Neus Villamor, Dolors Colomer
Journal: Blood (2006)
AB0149 Associations of Anti Nucleosome Antibody in Systemic Lupus Erythematosus in India
Authors: N. Gupta, J.K. Doss, H. Mohan, A. Nair, T. Sebastian, D. Danda
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Nucleosomes are basic elements of chromatin and are considered to be the major antigens in the pathophysiology of systemic lupus erythematosus (SLE). <h3>Objectives</h3> This study aimed to look for associations between anti nucleosome antibodies and clinical and laboratory parameters in SLE <h3>Methods</h3> This retrospective study was done in department of Clinical immunology &amp; Rheumatology in Christian Medical College, Vellore, India. Patients with SLE by SLICC 2012 criteria between March 2013 and September 2015 subjected to anti nucleosome antibody test formed the study cohort. A cut off of ≥20 U/ml by ELISA was defined as per manufacturer9s (Euroimmune, Germany) instructions. Associations of anti nucleosome antibody with clinical and laboratory parameters in SLE was studied. <h3>Results</h3> Anti nucleosome antibody was available for 238 patients with SLE. Mean age of the patients was 28.98±9.01 years with male to female ratio of 17: 221. Median disease duration was 8 (5–12) months prior to doing this test. Positive titers of anti nucleosome antibody (≥20 U/ml) were noted in 107 patients (46.5%). Renal involvement was seen in 134 (56.3%) patients. Univariate analysis reflected raised anti-c1q antibody, ESR, urinary protein creatinine ratio (UPC), anti dsDNA antibody, SLE disease activity index (SLEDAI), renal SLEDAI, low C3 and C4 as significant association of elevated anti nucleosome antibody levels. No significant association with arthritis, serositis, major infections, serositis, anti-phospholipid antibodies, autoimmune hematological cutaneous, neuropsychiatric, cardiovascular, respiratory, vasculitic and gastrointestinal manifestation was present. Multivariate regression analysis showed that raised anti-c1q antibodies and DsDna were associated with raised anti nucleosome antibody with odds ratio of 17.46 (95 CI: 1.46–213.86, p=0.02) and 82.94 (95 CI: 3.62–189.93, p=0.006) respectively. <h3>Conclusions</h3> As per literature search, this is the largest single centre study of anti nucleosome antibody in SLE. In this study, raised anti-c1q antibodies and DsDna were independently associated with raised anti nucleosome antibody in SLE. <h3>Disclosure of Interest</h3> None declared
Increased Proliferation of FoxP3 Regulatory T Cells after Allogeneic Hematopoietic Stem Cell Transplantation Is Counterbalanced by Increased Susceptibility to Apoptosis
Authors: Ken-ichi Matsuoka, Corey Cutler, John Koreth, Joseph H Antin, Robert J Soiffer, Jerome Ritz
Journal: Blood (2008)